Get Diamond plan for FREE

    logo

    ANI Pharmaceuticals, Inc. (ANIP)

    Price:

    90.12 USD

    ( + 0.41 USD)

    Your position:

    0 USD

    ACTION PANEL
    CREATE A NOTE
    ABOUT
    Symbol
    ANIP
    Name
    ANI Pharmaceuticals, Inc.
    Industry
    Drug Manufacturers - Specialty & Generic
    Sector
    Healthcare
    Price
    90.120
    Market Cap
    1.955B
    Enterprise value
    1.547B
    Currency
    USD
    Ceo
    Nikhil Lalwani
    Full Time Employees
    897
    Ipo Date
    2000-05-05
    City
    Baudette
    Address
    210 Main Street West

    Check the

    KEY TAKEAWAYS

    ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
    Descriptive alt text

    (REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION

    SIMILAR COMPANIES STI SCORE

    Similar STI Score

    Cronos Group Inc.

    VALUE SCORE:

    8

    Symbol
    CRON
    Market Cap
    943.947M
    Industry
    Drug Manufacturers - Specialty & Generic
    Sector
    Healthcare

    2nd position

    Amphastar Pharmaceuticals, Inc.

    VALUE SCORE:

    10

    Symbol
    AMPH
    Market Cap
    1.409B
    Industry
    Drug Manufacturers - Specialty & Generic
    Sector
    Healthcare

    The best

    Lantheus Holdings, Inc.

    VALUE SCORE:

    11

    Symbol
    LNTH
    Market Cap
    3.768B
    Industry
    Drug Manufacturers - Specialty & Generic
    Sector
    Healthcare
    FUNDAMENTALS
    P/E
    -162.038
    P/S
    2.615
    P/B
    4.093
    Debt/Equity
    0.733
    EV/FCF
    18.469
    Price to operating cash flow
    -1.000
    Price to free cash flow
    -1.000
    EV/sales
    2.752
    Earnings yield
    -0.006
    Debt/assets
    0.238
    FUNDAMENTALS
    Net debt/ebidta
    1.083
    Interest coverage
    0.616
    Research And Developement To Revenue
    0.072
    Intangile to total assets
    0.433
    Capex to operating cash flow
    0.228
    Capex to revenue
    0.043
    Capex to depreciation
    0.376
    Return on tangible assets
    -0.014
    Debt to market cap
    0.164
    Piotroski Score
    3.000
    FUNDAMENTALS
    PEG
    -4.003
    P/CF
    12.847
    P/FCF
    17.551
    RoA %
    -0.821
    RoIC %
    0.940
    Gross Profit Margin %
    57.949
    Quick Ratio
    1.960
    Current Ratio
    2.545
    Net Profit Margin %
    -1.476
    Net-Net
    -22.402
    FUNDAMENTALS PER SHARE
    FCF per share
    5.615
    Revenue per share
    37.683
    Net income per share
    -0.556
    Operating cash flow per share
    7.015
    Free cash flow per share
    5.615
    Cash per share
    11.269
    Book value per share
    22.021
    Tangible book value per share
    -7.265
    Shareholders equity per share
    22.021
    Interest debt per share
    17.382
    TECHNICAL
    52 weeks high
    91.150
    52 weeks low
    52.500
    Current trading session High
    91.090
    Current trading session Low
    88.820
    DIVIDEND
    Dividend yield
    0.00%
    Payout ratio
    -14.7%
    Years of div. Increase
    0
    Years of div.
    0
    Q-shift
    Dividend per share
    0
    SIMILAR COMPANIES
    logo

    Country
    IE
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    13.637
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Drug Manufacturers - Specialty & Generic
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    10.560
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Devices
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -2.041
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Drug Manufacturers - Specialty & Generic
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    27.394
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Drug Manufacturers - Specialty & Generic
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    1.161
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -1.937
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Drug Manufacturers - Specialty & Generic
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -7.423
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Drug Manufacturers - Specialty & Generic
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -8.951
    DESCRIPTION

    ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.

    NEWS
    https://images.financialmodelingprep.com/news/ani-anip-q2-earnings-how-key-metrics-compare-to-20250811.jpg
    ANI (ANIP) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

    zacks.com

    2025-08-11 10:31:30

    While the top- and bottom-line numbers for ANI (ANIP) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

    https://images.financialmodelingprep.com/news/ani-pharmaceuticals-inc-anip-q2-2025-earnings-call-transcript-20250808.jpg
    ANI Pharmaceuticals, Inc. (ANIP) Q2 2025 Earnings Call Transcript

    seekingalpha.com

    2025-08-08 15:56:48

    ANI Pharmaceuticals, Inc. (NASDAQ:ANIP ) Q2 2025 Earnings Conference Call August 8, 2025 8:30 AM ET Company Participants Christopher K. Mutz - Senior VP & Head of Rare Disease Nikhil Lalwani - President, CEO & Director Stephen P.

    https://images.financialmodelingprep.com/news/ani-pharmaceuticals-anip-q2-earnings-and-revenues-surpass-estimates-20250808.jpg
    ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Surpass Estimates

    zacks.com

    2025-08-08 09:00:20

    ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $1.8 per share, beating the Zacks Consensus Estimate of $1.38 per share. This compares to earnings of $1.02 per share a year ago.

    https://images.financialmodelingprep.com/news/ani-pharmaceuticals-reports-record-second-quarter-2025-financial-results-20250808.jpg
    ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 Guidance

    globenewswire.com

    2025-08-08 06:50:00

    BAUDETTE, Minn., Aug. 08, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the second quarter ended June 30, 2025.

    https://images.financialmodelingprep.com/news/ani-pharmaceuticals-to-discuss-second-quarter-2025-financial-results-20250801.jpg
    ANI Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 8, 2025, at 8:30 a.m. ET

    globenewswire.com

    2025-08-01 06:50:00

    PRINCETON, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its second quarter 2025 financial results on Friday, August 8, 2025, prior to the market open.

    https://images.financialmodelingprep.com/news/ani-pharmaceuticals-anip-earnings-expected-to-grow-what-to-20250729.jpg
    ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Q2 Release

    zacks.com

    2025-07-29 11:05:41

    ANI (ANIP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    https://images.financialmodelingprep.com/news/ani-pharmaceuticals-announces-results-from-new-day-clinical-trial-20250723.jpg
    ANI Pharmaceuticals Announces Results from NEW DAY Clinical Trial of ILUVIEN® for Use in Patients with Diabetic Macular Edema (DME)

    globenewswire.com

    2025-07-23 06:50:00

    Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the aflibercept arm

    https://images.financialmodelingprep.com/news/will-ani-anip-beat-estimates-again-in-its-next-20250714.jpg
    Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report?

    zacks.com

    2025-07-14 13:11:12

    ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

    https://images.financialmodelingprep.com/news/ani-pharmaceuticals-to-participate-at-leerink-partners-therapeutics-forum-20250702.jpg
    ANI Pharmaceuticals to Participate at Leerink Partners Therapeutics Forum: I&I and Metabolism on July 8th

    globenewswire.com

    2025-07-02 06:50:00

    PRINCETON, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, will host 1x1 meetings at the Leerink Partners Therapeutics Forum: I&I and Metabolism on Tuesday, July 8, 2025, in Boston, MA.

    https://images.financialmodelingprep.com/news/ani-pharmaceuticals-announces-presentation-of-new-preclinical-data-20250612.jpg
    ANI Pharmaceuticals Announces Presentation of New Preclinical Data

    globenewswire.com

    2025-06-12 07:00:00

    The Use of Purified Cortrophin® Gel in Murine Collagen-Induced Arthritis Mouse Model presented as a poster at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress The Use of Purified Cortrophin® Gel in Murine Collagen-Induced Arthritis Mouse Model presented as a poster at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress

    https://images.financialmodelingprep.com/news/ani-pharmaceuticals-to-present-at-the-2025-jefferies-global-healthcare-20250527.jpg
    ANI Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

    globenewswire.com

    2025-05-27 16:30:00

    PRINCETON, N.J., May 27, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will present at the 2025 Jefferies Global Healthcare Conference in New York City as follows:

    https://images.financialmodelingprep.com/news/ani-pharmaceuticals-announces-initiation-of-phase-4-clinical-trial-20250522.jpg
    ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin® Gel for the Treatment of Acute Gout Flares

    globenewswire.com

    2025-05-22 06:50:00

    Purified Cortrophin Gel is the only ACTH therapy approved by the FDA for the treatment of  acute gout flares Trial to be conducted by Dr. Hyon Choi at Massachusetts General Hospital and will compare the safety and efficacy of two dose levels of Purified Cortrophin Gel for the treatment of acute gout flares PRINCETON, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the initiation of a Phase 4 clinical trial at Massachusetts General Hospital to compare the safety and efficacy of two dose levels (40 USP units and 80 USP units) of Purified Cortrophin Gel (repository corticotropin injection USP) (Cortrophin Gel) for the treatment of acute gout flares.

    https://images.financialmodelingprep.com/news/ani-pharmaceuticals-to-participate-at-the-hc-wainwright-3rd-20250512.jpg
    ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual BioConnect Conference at NASDAQ

    globenewswire.com

    2025-05-12 18:30:00

    PRINCETON, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ as follows:

    https://images.financialmodelingprep.com/news/ani-anip-is-an-incredible-growth-stock-3-reasons-20250512.jpg
    ANI (ANIP) is an Incredible Growth Stock: 3 Reasons Why

    zacks.com

    2025-05-12 13:50:46

    ANI (ANIP) is well positioned to outperform the market, as it exhibits above-average growth in financials.

    https://images.financialmodelingprep.com/news/ani-pharmaceuticals-inc-anip-q1-2025-earnings-call-transcript-20250509.jpg
    ANI Pharmaceuticals, Inc. (ANIP) Q1 2025 Earnings Call Transcript

    seekingalpha.com

    2025-05-09 11:44:46

    ANI Pharmaceuticals, Inc. (NASDAQ:ANIP ) Q1 2025 Earnings Conference Call May 9, 2025 8:00 AM ET Company Participants Lisa Wilson - IR, Insight Communications Nikhil Lalwani - President, CEO & Director Christopher Mutz - SVP, Head, Rare Diseases Stephen Carey - CFO & SVP Conference Call Participants Gary Nachman - Raymond James Faisal Khurshid - Leerink Partners Vamil Divan - Guggenheim Securities David Amsellem - Piper Sandler Ekaterina Knyazkova - J.P. Morgan Les Sulewski - Truist Securities Operator Please stand by.

    https://images.financialmodelingprep.com/news/is-ani-pharmaceuticals-anip-outperforming-other-medical-stocks-this-20250509.jpg
    Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year?

    zacks.com

    2025-05-09 10:46:24

    Here is how ANI Pharmaceuticals (ANIP) and Agenus (AGEN) have performed compared to their sector so far this year.